HEADER GENE REGULATION 14-JAN-21 7LEM TITLE CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN (BD1) OF HUMAN BRDT BOUND TITLE 2 TO LRRK2-IN-1 COMPND MOL_ID: 1; COMPND 2 MOLECULE: BROMODOMAIN TESTIS-SPECIFIC PROTEIN; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: CANCER/TESTIS ANTIGEN 9,CT9,RING3-LIKE PROTEIN; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BRDT; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS BROMODOMAIN, LRRK, KINASE, GENE REGULATION EXPDTA X-RAY DIFFRACTION AUTHOR A.CHAN,M.R.KARIM,E.SCHONBRUNN REVDAT 4 18-OCT-23 7LEM 1 REMARK REVDAT 3 24-NOV-21 7LEM 1 JRNL REVDAT 2 17-NOV-21 7LEM 1 JRNL REVDAT 1 14-JUL-21 7LEM 0 JRNL AUTH R.M.KARIM,M.J.BIKOWITZ,A.CHAN,J.Y.ZHU,D.GRASSIE,A.BECKER, JRNL AUTH 2 N.BERNDT,S.GUNAWAN,N.J.LAWRENCE,E.SCHONBRUNN JRNL TITL DIFFERENTIAL BET BROMODOMAIN INHIBITION BY JRNL TITL 2 DIHYDROPTERIDINONE AND PYRIMIDODIAZEPINONE KINASE JRNL TITL 3 INHIBITORS. JRNL REF J.MED.CHEM. V. 64 15772 2021 JRNL REFN ISSN 0022-2623 JRNL PMID 34710325 JRNL DOI 10.1021/ACS.JMEDCHEM.1C01096 REMARK 2 REMARK 2 RESOLUTION. 1.89 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.15.2_3472 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.89 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 35.25 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.360 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.8 REMARK 3 NUMBER OF REFLECTIONS : 23487 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.203 REMARK 3 R VALUE (WORKING SET) : 0.200 REMARK 3 FREE R VALUE : 0.247 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1198 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 35.2500 - 3.9294 0.99 2604 140 0.1697 0.2265 REMARK 3 2 3.9294 - 3.1195 0.99 2504 134 0.1898 0.2255 REMARK 3 3 3.1195 - 2.7253 1.00 2487 134 0.2169 0.2646 REMARK 3 4 2.7253 - 2.4762 0.99 2480 133 0.2096 0.2527 REMARK 3 5 2.4762 - 2.2988 0.99 2459 132 0.2136 0.2529 REMARK 3 6 2.2988 - 2.1633 0.99 2472 133 0.2116 0.2670 REMARK 3 7 2.1633 - 2.0549 0.98 2458 132 0.2234 0.2652 REMARK 3 8 2.0549 - 1.9655 0.99 2432 131 0.2522 0.2901 REMARK 3 9 1.9655 - 1.8900 0.97 2393 129 0.2888 0.3448 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.170 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 30.520 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 34.85 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 44.69 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : NULL NULL REMARK 3 ANGLE : NULL NULL REMARK 3 CHIRALITY : NULL NULL REMARK 3 PLANARITY : NULL NULL REMARK 3 DIHEDRAL : NULL NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 1 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: ALL REMARK 3 ORIGIN FOR THE GROUP (A): -8.1012 -2.6173 -21.4932 REMARK 3 T TENSOR REMARK 3 T11: 0.3363 T22: 0.2050 REMARK 3 T33: 0.2623 T12: 0.0494 REMARK 3 T13: -0.0268 T23: -0.0049 REMARK 3 L TENSOR REMARK 3 L11: 2.3959 L22: 1.6556 REMARK 3 L33: 0.6987 L12: -0.1904 REMARK 3 L13: -0.0794 L23: -0.1525 REMARK 3 S TENSOR REMARK 3 S11: -0.1214 S12: -0.3224 S13: 0.0063 REMARK 3 S21: 0.5541 S22: 0.1065 S23: -0.2039 REMARK 3 S31: -0.0342 S32: 0.0165 S33: 0.0200 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7LEM COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 15-JAN-21. REMARK 100 THE DEPOSITION ID IS D_1000253740. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 20-JUN-19 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 22-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9700 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS EIGER X 16M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 23495 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.890 REMARK 200 RESOLUTION RANGE LOW (A) : 35.250 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.7 REMARK 200 DATA REDUNDANCY : 3.645 REMARK 200 R MERGE (I) : 0.04300 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.1400 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.89 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.94 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.7 REMARK 200 DATA REDUNDANCY IN SHELL : 3.68 REMARK 200 R MERGE FOR SHELL (I) : 0.50900 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.630 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 7L73 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55.33 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.75 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.2 M (NH4)2SO4, 0.1 M SODIUM REMARK 280 CACODYLATE TRIHYDRATE (PH 6.5), AND 30 % W/V PEG 8,000, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 15.01000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 25 REMARK 465 ALA A 26 REMARK 465 ALA A 27 REMARK 465 SER A 28 REMARK 465 GLU A 137 REMARK 465 GLY B 25 REMARK 465 ALA B 26 REMARK 465 ALA B 27 REMARK 465 SER B 28 REMARK 465 GLU B 137 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS B 86 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O SER A 47 O HOH A 301 2.11 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLN A 62 63.19 66.37 REMARK 500 GLN B 135 -148.92 -115.27 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 4K4 A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 202 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 203 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 204 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 205 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 206 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 4K4 B 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO B 202 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO B 203 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO B 204 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO B 205 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO B 206 DBREF 7LEM A 29 137 UNP Q58F21 BRDT_HUMAN 42 150 DBREF 7LEM B 29 137 UNP Q58F21 BRDT_HUMAN 42 150 SEQADV 7LEM GLY A 25 UNP Q58F21 EXPRESSION TAG SEQADV 7LEM ALA A 26 UNP Q58F21 EXPRESSION TAG SEQADV 7LEM ALA A 27 UNP Q58F21 EXPRESSION TAG SEQADV 7LEM SER A 28 UNP Q58F21 EXPRESSION TAG SEQADV 7LEM GLY B 25 UNP Q58F21 EXPRESSION TAG SEQADV 7LEM ALA B 26 UNP Q58F21 EXPRESSION TAG SEQADV 7LEM ALA B 27 UNP Q58F21 EXPRESSION TAG SEQADV 7LEM SER B 28 UNP Q58F21 EXPRESSION TAG SEQRES 1 A 113 GLY ALA ALA SER THR ASN GLN LEU GLN TYR LEU GLN LYS SEQRES 2 A 113 VAL VAL LEU LYS ASP LEU TRP LYS HIS SER PHE SER TRP SEQRES 3 A 113 PRO PHE GLN ARG PRO VAL ASP ALA VAL LYS LEU GLN LEU SEQRES 4 A 113 PRO ASP TYR TYR THR ILE ILE LYS ASN PRO MET ASP LEU SEQRES 5 A 113 ASN THR ILE LYS LYS ARG LEU GLU ASN LYS TYR TYR ALA SEQRES 6 A 113 LYS ALA SER GLU CYS ILE GLU ASP PHE ASN THR MET PHE SEQRES 7 A 113 SER ASN CYS TYR LEU TYR ASN LYS PRO GLY ASP ASP ILE SEQRES 8 A 113 VAL LEU MET ALA GLN ALA LEU GLU LYS LEU PHE MET GLN SEQRES 9 A 113 LYS LEU SER GLN MET PRO GLN GLU GLU SEQRES 1 B 113 GLY ALA ALA SER THR ASN GLN LEU GLN TYR LEU GLN LYS SEQRES 2 B 113 VAL VAL LEU LYS ASP LEU TRP LYS HIS SER PHE SER TRP SEQRES 3 B 113 PRO PHE GLN ARG PRO VAL ASP ALA VAL LYS LEU GLN LEU SEQRES 4 B 113 PRO ASP TYR TYR THR ILE ILE LYS ASN PRO MET ASP LEU SEQRES 5 B 113 ASN THR ILE LYS LYS ARG LEU GLU ASN LYS TYR TYR ALA SEQRES 6 B 113 LYS ALA SER GLU CYS ILE GLU ASP PHE ASN THR MET PHE SEQRES 7 B 113 SER ASN CYS TYR LEU TYR ASN LYS PRO GLY ASP ASP ILE SEQRES 8 B 113 VAL LEU MET ALA GLN ALA LEU GLU LYS LEU PHE MET GLN SEQRES 9 B 113 LYS LEU SER GLN MET PRO GLN GLU GLU HET 4K4 A 201 42 HET EDO A 202 4 HET EDO A 203 4 HET EDO A 204 4 HET EDO A 205 4 HET EDO A 206 4 HET 4K4 B 201 42 HET EDO B 202 4 HET EDO B 203 4 HET EDO B 204 4 HET EDO B 205 4 HET EDO B 206 4 HETNAM 4K4 2-[(2-METHOXY-4-{[4-(4-METHYLPIPERAZIN-1-YL)PIPERIDIN- HETNAM 2 4K4 1-YL]CARBONYL}PHENYL)AMINO]-5,11-DIMETHYL-5,11- HETNAM 3 4K4 DIHYDRO-6H-PYRIMIDO[4,5-B][1,4]BENZODIAZEPIN-6-ONE HETNAM EDO 1,2-ETHANEDIOL HETSYN EDO ETHYLENE GLYCOL FORMUL 3 4K4 2(C31 H38 N8 O3) FORMUL 4 EDO 10(C2 H6 O2) FORMUL 15 HOH *88(H2 O) HELIX 1 AA1 THR A 29 VAL A 38 1 10 HELIX 2 AA2 VAL A 38 HIS A 46 1 9 HELIX 3 AA3 SER A 47 GLN A 53 5 7 HELIX 4 AA4 ASP A 57 GLN A 62 1 6 HELIX 5 AA5 ASP A 65 ILE A 70 1 6 HELIX 6 AA6 ASP A 75 ASN A 85 1 11 HELIX 7 AA7 LYS A 90 ASN A 109 1 20 HELIX 8 AA8 ASP A 113 GLN A 132 1 20 HELIX 9 AA9 ASN B 30 VAL B 38 1 9 HELIX 10 AB1 VAL B 38 HIS B 46 1 9 HELIX 11 AB2 SER B 47 GLN B 53 5 7 HELIX 12 AB3 ASP B 57 GLN B 62 1 6 HELIX 13 AB4 ASP B 65 ILE B 70 1 6 HELIX 14 AB5 ASP B 75 ASN B 85 1 11 HELIX 15 AB6 LYS B 90 ASN B 109 1 20 HELIX 16 AB7 ASP B 113 SER B 131 1 19 SITE 1 AC1 12 TRP A 50 PRO A 51 PHE A 52 LYS A 60 SITE 2 AC1 12 LEU A 61 GLN A 62 LEU A 63 TYR A 108 SITE 3 AC1 12 ASN A 109 ILE A 115 EDO A 205 HOH A 305 SITE 1 AC2 3 PRO A 55 ASN A 77 THR A 78 SITE 1 AC3 2 LYS A 41 TRP A 44 SITE 1 AC4 2 ASP A 65 TYR A 108 SITE 1 AC5 5 TRP A 50 PRO A 55 VAL A 56 ASP A 57 SITE 2 AC5 5 4K4 A 201 SITE 1 AC6 4 LYS A 71 ASN A 72 ASP A 114 LEU A 117 SITE 1 AC7 12 TRP B 50 PRO B 51 PHE B 52 LYS B 60 SITE 2 AC7 12 LEU B 61 GLN B 62 LEU B 63 TYR B 108 SITE 3 AC7 12 ASN B 109 ILE B 115 EDO B 205 HOH B 305 SITE 1 AC8 4 ARG B 54 PRO B 55 ASN B 77 THR B 78 SITE 1 AC9 3 ASP B 57 HOH B 314 HOH B 327 SITE 1 AD1 2 LYS B 41 TRP B 44 SITE 1 AD2 5 TRP B 50 PRO B 55 VAL B 56 ASP B 57 SITE 2 AD2 5 4K4 B 201 SITE 1 AD3 4 LYS B 71 ASP B 114 LEU B 117 HOH B 340 CRYST1 69.220 30.020 72.840 90.00 104.56 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.014447 0.000000 0.003753 0.00000 SCALE2 0.000000 0.033311 0.000000 0.00000 SCALE3 0.000000 0.000000 0.014185 0.00000